ParkinsonCanadaV1, PascalFrancis, Corpus, bibRecord, 000040

The effects of dopaminergic medication on dynamic decision making in Parkinson's disease

Identifieur interne : 000040 ( PascalFrancis/Corpus ); précédent : 000039; suivant : 000041

The effects of dopaminergic medication on dynamic decision making in Parkinson's disease

Auteurs : Magda Osman ; Agata Rytersk ; Kash Karimi ; LINGLING TU ; Ignacio Obeso ; Maarten Speekenbrink ; Marjan Jahanshahi

Source :

Neuropsychologia [ 0028-3932 ] ; 2014.

RBID : Pascal:14-0055586

Descripteurs français

Pascal (Inist)
- Dopamine, Prise de décision, Maladie de Parkinson, Prédiction, Surdosage, Apprentissage, Antiparkinsonien, Homme.

English descriptors

KwdEn :
- Antiparkinson agent, Decision making, Dopamine, Human, Learning, Overdosing, Parkinson disease, Prediction.

Abstract

In the present study we address the following questions: (1) How is performance affected when patients with Parkinson's Disease (PD) perform a dynamic decision making task? (2) Does dopaminergic medication differentially affect dynamic decision making? To address these questions participants were trained with different goals during learning: either they made intervention-based decisions or prediction-based decisions during learning. The findings show that overall there is an advantage for those trained to intervene over those trained to predict. In addition, the results are the first demonstration that PD patients 'ON' (N=20) compared to 'OFF' L-Dopa (N=15) medication and also relative to healthy age matched controls (N=16) showed lower levels of relative improvement in the accuracy of their decisions in a dynamic decision making task, and tended to use sub-optimal strategies. These findings provide support for the 'Dopamine Overdose' hypothesis using a novel decision making task, and suggest that executive functions such as decision making can be adversely affected by dopaminergic medication in PD.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0028-3932`
A02	`01`			`@0 NUPSA6`
A03		`1`		`@0 Neuropsychologia`
A05				`@2 53`
A08	`01`	`1`	`ENG`	`@1 The effects of dopaminergic medication on dynamic decision making in Parkinson's disease`
A11	`01`	`1`		`@1 OSMAN (Magda)`
A11	`02`	`1`		`@1 RYTERSK (Agata)`
A11	`03`	`1`		`@1 KARIMI (Kash)`
A11	`04`	`1`		`@1 LINGLING TU`
A11	`05`	`1`		`@1 OBESO (Ignacio)`
A11	`06`	`1`		`@1 SPEEKENBRINK (Maarten)`
A11	`07`	`1`		`@1 JAHANSHAHI (Marjan)`
A14	`01`			`@1 Biological and Experimental Psychology, School of Biological and Chemical Sciences, Queen Mary University of London, Mile End Road @2 London E1 4NS @3 GBR @Z 1 aut. @Z 2 aut.`
A14	`02`			`@1 Sobell Department of Motor Neuroscience and Movement Disorders, The National Hospital for Neurology and Neurosurgery, UCL Institute of Neurology, 33 Queen Square @2 London WC1N 3 BG @3 GBR @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 7 aut.`
A14	`03`			`@1 Department of Psychiatry, Sir Run Run Shaw Hospital, 3 East Qingchun Road @2 310016 Hangzhou, Zhejiang @3 CHN @Z 4 aut.`
A14	`04`			`@1 Psychology Department at the St. George Campus, University of Toronto, 100 St. George Street, 4th Floor, Sidney Smith Hall @2 Toronto, Ontario, M5S 3G3 @3 CAN @Z 5 aut.`
A14	`05`			`@1 Cognitive, Perceptual and Brain Sciences, University College London, 26 Bedford Way @2 London WC1H 0AP @3 GBR @Z 1 aut. @Z 6 aut.`
A20				`@1 157-164`
A21				`@1 2014`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 11143 @5 354000505714970160`
A44				`@0 0000 @1 © 2014 INIST-CNRS. All rights reserved.`
A45				`@0 1/2 p.`
A47	`01`	`1`		`@0 14-0055586`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Neuropsychologia`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 In the present study we address the following questions: (1) How is performance affected when patients with Parkinson's Disease (PD) perform a dynamic decision making task? (2) Does dopaminergic medication differentially affect dynamic decision making? To address these questions participants were trained with different goals during learning: either they made intervention-based decisions or prediction-based decisions during learning. The findings show that overall there is an advantage for those trained to intervene over those trained to predict. In addition, the results are the first demonstration that PD patients 'ON' (N=20) compared to 'OFF' L-Dopa (N=15) medication and also relative to healthy age matched controls (N=16) showed lower levels of relative improvement in the accuracy of their decisions in a dynamic decision making task, and tended to use sub-optimal strategies. These findings provide support for the 'Dopamine Overdose' hypothesis using a novel decision making task, and suggest that executive functions such as decision making can be adversely affected by dopaminergic medication in PD.
C02	`01`	`X`		`@0 002B18C13`
C02	`02`	`X`		`@0 002B17G`
C02	`03`	`X`		`@0 002B17A01`
C03	`01`	`X`	`FRE`	`@0 Dopamine @2 NK @2 FR @5 01`
C03	`01`	`X`	`ENG`	`@0 Dopamine @2 NK @2 FR @5 01`
C03	`01`	`X`	`SPA`	`@0 Dopamina @2 NK @2 FR @5 01`
C03	`02`	`X`	`FRE`	`@0 Prise de décision @5 02`
C03	`02`	`X`	`ENG`	`@0 Decision making @5 02`
C03	`02`	`X`	`SPA`	`@0 Toma decision @5 02`
C03	`03`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 03`
C03	`03`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 03`
C03	`03`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 03`
C03	`04`	`X`	`FRE`	`@0 Prédiction @5 04`
C03	`04`	`X`	`ENG`	`@0 Prediction @5 04`
C03	`04`	`X`	`SPA`	`@0 Predicción @5 04`
C03	`05`	`X`	`FRE`	`@0 Surdosage @5 05`
C03	`05`	`X`	`ENG`	`@0 Overdosing @5 05`
C03	`05`	`X`	`SPA`	`@0 Sobredosificación @5 05`
C03	`06`	`X`	`FRE`	`@0 Apprentissage @5 06`
C03	`06`	`X`	`ENG`	`@0 Learning @5 06`
C03	`06`	`X`	`SPA`	`@0 Aprendizaje @5 06`
C03	`07`	`X`	`FRE`	`@0 Antiparkinsonien @5 07`
C03	`07`	`X`	`ENG`	`@0 Antiparkinson agent @5 07`
C03	`07`	`X`	`SPA`	`@0 Antiparkinsoniano @5 07`
C03	`08`	`X`	`FRE`	`@0 Homme @5 18`
C03	`08`	`X`	`ENG`	`@0 Human @5 18`
C03	`08`	`X`	`SPA`	`@0 Hombre @5 18`
C07	`01`	`X`	`FRE`	`@0 Catécholamine @5 37`
C07	`01`	`X`	`ENG`	`@0 Catecholamine @5 37`
C07	`01`	`X`	`SPA`	`@0 Catecolamina @5 37`
C07	`02`	`X`	`FRE`	`@0 Neurotransmetteur @5 38`
C07	`02`	`X`	`ENG`	`@0 Neurotransmitter @5 38`
C07	`02`	`X`	`SPA`	`@0 Neurotransmisor @5 38`
C07	`03`	`X`	`FRE`	`@0 Cognition @5 39`
C07	`03`	`X`	`ENG`	`@0 Cognition @5 39`
C07	`03`	`X`	`SPA`	`@0 Cognición @5 39`
C07	`04`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 40`
C07	`04`	`X`	`ENG`	`@0 Cerebral disorder @5 40`
C07	`04`	`X`	`SPA`	`@0 Encéfalo patología @5 40`
C07	`05`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 41`
C07	`05`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 41`
C07	`05`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 41`
C07	`06`	`X`	`FRE`	`@0 Maladie dégénérative @5 42`
C07	`06`	`X`	`ENG`	`@0 Degenerative disease @5 42`
C07	`06`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 42`
C07	`07`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 43`
C07	`07`	`X`	`ENG`	`@0 Central nervous system disease @5 43`
C07	`07`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 43`
C07	`08`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 44`
C07	`08`	`X`	`ENG`	`@0 Nervous system diseases @5 44`
C07	`08`	`X`	`SPA`	`@0 Sistema nervioso patología @5 44`
C07	`09`	`X`	`FRE`	`@0 Processus acquisition @5 45`
C07	`09`	`X`	`ENG`	`@0 Acquisition process @5 45`
C07	`09`	`X`	`SPA`	`@0 Proceso adquisición @5 45`
N21				`@1 069`

Format Inist (serveur)

NO :	PASCAL 14-0055586 INIST
ET :	The effects of dopaminergic medication on dynamic decision making in Parkinson's disease
AU :	OSMAN (Magda); RYTERSK (Agata); KARIMI (Kash); LINGLING TU; OBESO (Ignacio); SPEEKENBRINK (Maarten); JAHANSHAHI (Marjan)
AF :	Biological and Experimental Psychology, School of Biological and Chemical Sciences, Queen Mary University of London, Mile End Road/London E1 4NS/Royaume-Uni (1 aut., 2 aut.); Sobell Department of Motor Neuroscience and Movement Disorders, The National Hospital for Neurology and Neurosurgery, UCL Institute of Neurology, 33 Queen Square/London WC1N 3 BG/Royaume-Uni (1 aut., 2 aut., 3 aut., 7 aut.); Department of Psychiatry, Sir Run Run Shaw Hospital, 3 East Qingchun Road/310016 Hangzhou, Zhejiang/Chine (4 aut.); Psychology Department at the St. George Campus, University of Toronto, 100 St. George Street, 4th Floor, Sidney Smith Hall/Toronto, Ontario, M5S 3G3/Canada (5 aut.); Cognitive, Perceptual and Brain Sciences, University College London, 26 Bedford Way/London WC1H 0AP/Royaume-Uni (1 aut., 6 aut.)
DT :	Publication en série; Niveau analytique
SO :	Neuropsychologia; ISSN 0028-3932; Coden NUPSA6; Royaume-Uni; Da. 2014; Vol. 53; Pp. 157-164; Bibl. 1/2 p.
LA :	Anglais
EA :	In the present study we address the following questions: (1) How is performance affected when patients with Parkinson's Disease (PD) perform a dynamic decision making task? (2) Does dopaminergic medication differentially affect dynamic decision making? To address these questions participants were trained with different goals during learning: either they made intervention-based decisions or prediction-based decisions during learning. The findings show that overall there is an advantage for those trained to intervene over those trained to predict. In addition, the results are the first demonstration that PD patients 'ON' (N=20) compared to 'OFF' L-Dopa (N=15) medication and also relative to healthy age matched controls (N=16) showed lower levels of relative improvement in the accuracy of their decisions in a dynamic decision making task, and tended to use sub-optimal strategies. These findings provide support for the 'Dopamine Overdose' hypothesis using a novel decision making task, and suggest that executive functions such as decision making can be adversely affected by dopaminergic medication in PD.
CC :	002B18C13; 002B17G; 002B17A01
FD :	Dopamine; Prise de décision; Maladie de Parkinson; Prédiction; Surdosage; Apprentissage; Antiparkinsonien; Homme
FG :	Catécholamine; Neurotransmetteur; Cognition; Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central; Pathologie du système nerveux; Processus acquisition
ED :	Dopamine; Decision making; Parkinson disease; Prediction; Overdosing; Learning; Antiparkinson agent; Human
EG :	Catecholamine; Neurotransmitter; Cognition; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Nervous system diseases; Acquisition process
SD :	Dopamina; Toma decision; Parkinson enfermedad; Predicción; Sobredosificación; Aprendizaje; Antiparkinsoniano; Hombre
LO :	INIST-11143.354000505714970160
ID :	14-0055586

Links to Exploration step

Pascal:14-0055586

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">The effects of dopaminergic medication on dynamic decision making in Parkinson's disease</title>
<author><name sortKey="Osman, Magda" sort="Osman, Magda" uniqKey="Osman M" first="Magda" last="Osman">Magda Osman</name>
<affiliation><inist:fA14 i1="01"><s1>Biological and Experimental Psychology, School of Biological and Chemical Sciences, Queen Mary University of London, Mile End Road</s1>
<s2>London E1 4NS</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Sobell Department of Motor Neuroscience and Movement Disorders, The National Hospital for Neurology and Neurosurgery, UCL Institute of Neurology, 33 Queen Square</s1>
<s2>London WC1N 3 BG</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>Cognitive, Perceptual and Brain Sciences, University College London, 26 Bedford Way</s1>
<s2>London WC1H 0AP</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rytersk, Agata" sort="Rytersk, Agata" uniqKey="Rytersk A" first="Agata" last="Rytersk">Agata Rytersk</name>
<affiliation><inist:fA14 i1="01"><s1>Biological and Experimental Psychology, School of Biological and Chemical Sciences, Queen Mary University of London, Mile End Road</s1>
<s2>London E1 4NS</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Sobell Department of Motor Neuroscience and Movement Disorders, The National Hospital for Neurology and Neurosurgery, UCL Institute of Neurology, 33 Queen Square</s1>
<s2>London WC1N 3 BG</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Karimi, Kash" sort="Karimi, Kash" uniqKey="Karimi K" first="Kash" last="Karimi">Kash Karimi</name>
<affiliation><inist:fA14 i1="02"><s1>Sobell Department of Motor Neuroscience and Movement Disorders, The National Hospital for Neurology and Neurosurgery, UCL Institute of Neurology, 33 Queen Square</s1>
<s2>London WC1N 3 BG</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lingling Tu" sort="Lingling Tu" uniqKey="Lingling Tu" last="Lingling Tu">LINGLING TU</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Psychiatry, Sir Run Run Shaw Hospital, 3 East Qingchun Road</s1>
<s2>310016 Hangzhou, Zhejiang</s2>
<s3>CHN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Obeso, Ignacio" sort="Obeso, Ignacio" uniqKey="Obeso I" first="Ignacio" last="Obeso">Ignacio Obeso</name>
<affiliation><inist:fA14 i1="04"><s1>Psychology Department at the St. George Campus, University of Toronto, 100 St. George Street, 4th Floor, Sidney Smith Hall</s1>
<s2>Toronto, Ontario, M5S 3G3</s2>
<s3>CAN</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Speekenbrink, Maarten" sort="Speekenbrink, Maarten" uniqKey="Speekenbrink M" first="Maarten" last="Speekenbrink">Maarten Speekenbrink</name>
<affiliation><inist:fA14 i1="05"><s1>Cognitive, Perceptual and Brain Sciences, University College London, 26 Bedford Way</s1>
<s2>London WC1H 0AP</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jahanshahi, Marjan" sort="Jahanshahi, Marjan" uniqKey="Jahanshahi M" first="Marjan" last="Jahanshahi">Marjan Jahanshahi</name>
<affiliation><inist:fA14 i1="02"><s1>Sobell Department of Motor Neuroscience and Movement Disorders, The National Hospital for Neurology and Neurosurgery, UCL Institute of Neurology, 33 Queen Square</s1>
<s2>London WC1N 3 BG</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">14-0055586</idno>
<date when="2014">2014</date>
<idno type="stanalyst">PASCAL 14-0055586 INIST</idno>
<idno type="RBID">Pascal:14-0055586</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000040</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">The effects of dopaminergic medication on dynamic decision making in Parkinson's disease</title>
<author><name sortKey="Osman, Magda" sort="Osman, Magda" uniqKey="Osman M" first="Magda" last="Osman">Magda Osman</name>
<affiliation><inist:fA14 i1="01"><s1>Biological and Experimental Psychology, School of Biological and Chemical Sciences, Queen Mary University of London, Mile End Road</s1>
<s2>London E1 4NS</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Sobell Department of Motor Neuroscience and Movement Disorders, The National Hospital for Neurology and Neurosurgery, UCL Institute of Neurology, 33 Queen Square</s1>
<s2>London WC1N 3 BG</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>Cognitive, Perceptual and Brain Sciences, University College London, 26 Bedford Way</s1>
<s2>London WC1H 0AP</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rytersk, Agata" sort="Rytersk, Agata" uniqKey="Rytersk A" first="Agata" last="Rytersk">Agata Rytersk</name>
<affiliation><inist:fA14 i1="01"><s1>Biological and Experimental Psychology, School of Biological and Chemical Sciences, Queen Mary University of London, Mile End Road</s1>
<s2>London E1 4NS</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Sobell Department of Motor Neuroscience and Movement Disorders, The National Hospital for Neurology and Neurosurgery, UCL Institute of Neurology, 33 Queen Square</s1>
<s2>London WC1N 3 BG</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Karimi, Kash" sort="Karimi, Kash" uniqKey="Karimi K" first="Kash" last="Karimi">Kash Karimi</name>
<affiliation><inist:fA14 i1="02"><s1>Sobell Department of Motor Neuroscience and Movement Disorders, The National Hospital for Neurology and Neurosurgery, UCL Institute of Neurology, 33 Queen Square</s1>
<s2>London WC1N 3 BG</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lingling Tu" sort="Lingling Tu" uniqKey="Lingling Tu" last="Lingling Tu">LINGLING TU</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Psychiatry, Sir Run Run Shaw Hospital, 3 East Qingchun Road</s1>
<s2>310016 Hangzhou, Zhejiang</s2>
<s3>CHN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Obeso, Ignacio" sort="Obeso, Ignacio" uniqKey="Obeso I" first="Ignacio" last="Obeso">Ignacio Obeso</name>
<affiliation><inist:fA14 i1="04"><s1>Psychology Department at the St. George Campus, University of Toronto, 100 St. George Street, 4th Floor, Sidney Smith Hall</s1>
<s2>Toronto, Ontario, M5S 3G3</s2>
<s3>CAN</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Speekenbrink, Maarten" sort="Speekenbrink, Maarten" uniqKey="Speekenbrink M" first="Maarten" last="Speekenbrink">Maarten Speekenbrink</name>
<affiliation><inist:fA14 i1="05"><s1>Cognitive, Perceptual and Brain Sciences, University College London, 26 Bedford Way</s1>
<s2>London WC1H 0AP</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jahanshahi, Marjan" sort="Jahanshahi, Marjan" uniqKey="Jahanshahi M" first="Marjan" last="Jahanshahi">Marjan Jahanshahi</name>
<affiliation><inist:fA14 i1="02"><s1>Sobell Department of Motor Neuroscience and Movement Disorders, The National Hospital for Neurology and Neurosurgery, UCL Institute of Neurology, 33 Queen Square</s1>
<s2>London WC1N 3 BG</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Neuropsychologia</title>
<title level="j" type="abbreviated">Neuropsychologia</title>
<idno type="ISSN">0028-3932</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Neuropsychologia</title>
<title level="j" type="abbreviated">Neuropsychologia</title>
<idno type="ISSN">0028-3932</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson agent</term>
<term>Decision making</term>
<term>Dopamine</term>
<term>Human</term>
<term>Learning</term>
<term>Overdosing</term>
<term>Parkinson disease</term>
<term>Prediction</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Dopamine</term>
<term>Prise de décision</term>
<term>Maladie de Parkinson</term>
<term>Prédiction</term>
<term>Surdosage</term>
<term>Apprentissage</term>
<term>Antiparkinsonien</term>
<term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">In the present study we address the following questions: (1) How is performance affected when patients with Parkinson's Disease (PD) perform a dynamic decision making task? (2) Does dopaminergic medication differentially affect dynamic decision making? To address these questions participants were trained with different goals during learning: either they made intervention-based decisions or prediction-based decisions during learning. The findings show that overall there is an advantage for those trained to intervene over those trained to predict. In addition, the results are the first demonstration that PD patients 'ON' (N=20) compared to 'OFF' L-Dopa (N=15) medication and also relative to healthy age matched controls (N=16) showed lower levels of relative improvement in the accuracy of their decisions in a dynamic decision making task, and tended to use sub-optimal strategies. These findings provide support for the 'Dopamine Overdose' hypothesis using a novel decision making task, and suggest that executive functions such as decision making can be adversely affected by dopaminergic medication in PD.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0028-3932</s0>
</fA01>
<fA02 i1="01"><s0>NUPSA6</s0>
</fA02>
<fA03 i2="1"><s0>Neuropsychologia</s0>
</fA03>
<fA05><s2>53</s2>
</fA05>
<fA08 i1="01" i2="1" l="ENG"><s1>The effects of dopaminergic medication on dynamic decision making in Parkinson's disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>OSMAN (Magda)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>RYTERSK (Agata)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>KARIMI (Kash)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>LINGLING TU</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>OBESO (Ignacio)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>SPEEKENBRINK (Maarten)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>JAHANSHAHI (Marjan)</s1>
</fA11>
<fA14 i1="01"><s1>Biological and Experimental Psychology, School of Biological and Chemical Sciences, Queen Mary University of London, Mile End Road</s1>
<s2>London E1 4NS</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Sobell Department of Motor Neuroscience and Movement Disorders, The National Hospital for Neurology and Neurosurgery, UCL Institute of Neurology, 33 Queen Square</s1>
<s2>London WC1N 3 BG</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Psychiatry, Sir Run Run Shaw Hospital, 3 East Qingchun Road</s1>
<s2>310016 Hangzhou, Zhejiang</s2>
<s3>CHN</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Psychology Department at the St. George Campus, University of Toronto, 100 St. George Street, 4th Floor, Sidney Smith Hall</s1>
<s2>Toronto, Ontario, M5S 3G3</s2>
<s3>CAN</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Cognitive, Perceptual and Brain Sciences, University College London, 26 Bedford Way</s1>
<s2>London WC1H 0AP</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA20><s1>157-164</s1>
</fA20>
<fA21><s1>2014</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>11143</s2>
<s5>354000505714970160</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2014 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>1/2 p.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>14-0055586</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Neuropsychologia</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>In the present study we address the following questions: (1) How is performance affected when patients with Parkinson's Disease (PD) perform a dynamic decision making task? (2) Does dopaminergic medication differentially affect dynamic decision making? To address these questions participants were trained with different goals during learning: either they made intervention-based decisions or prediction-based decisions during learning. The findings show that overall there is an advantage for those trained to intervene over those trained to predict. In addition, the results are the first demonstration that PD patients 'ON' (N=20) compared to 'OFF' L-Dopa (N=15) medication and also relative to healthy age matched controls (N=16) showed lower levels of relative improvement in the accuracy of their decisions in a dynamic decision making task, and tended to use sub-optimal strategies. These findings provide support for the 'Dopamine Overdose' hypothesis using a novel decision making task, and suggest that executive functions such as decision making can be adversely affected by dopaminergic medication in PD.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B18C13</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B17A01</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Dopamina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Prise de décision</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Decision making</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Toma decision</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Prédiction</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Prediction</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Predicción</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Surdosage</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Overdosing</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Sobredosificación</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Apprentissage</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Learning</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Aprendizaje</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Homme</s0>
<s5>18</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Human</s0>
<s5>18</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Hombre</s0>
<s5>18</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Catécholamine</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Catecholamine</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Catecolamina</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Neurotransmetteur</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Neurotransmitter</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Neurotransmisor</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Cognition</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cognition</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Cognición</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>42</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>43</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>43</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>43</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>44</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>44</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>44</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Processus acquisition</s0>
<s5>45</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Acquisition process</s0>
<s5>45</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Proceso adquisición</s0>
<s5>45</s5>
</fC07>
<fN21><s1>069</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 14-0055586 INIST</NO>
<ET>The effects of dopaminergic medication on dynamic decision making in Parkinson's disease</ET>
<AU>OSMAN (Magda); RYTERSK (Agata); KARIMI (Kash); LINGLING TU; OBESO (Ignacio); SPEEKENBRINK (Maarten); JAHANSHAHI (Marjan)</AU>
<AF>Biological and Experimental Psychology, School of Biological and Chemical Sciences, Queen Mary University of London, Mile End Road/London E1 4NS/Royaume-Uni (1 aut., 2 aut.); Sobell Department of Motor Neuroscience and Movement Disorders, The National Hospital for Neurology and Neurosurgery, UCL Institute of Neurology, 33 Queen Square/London WC1N 3 BG/Royaume-Uni (1 aut., 2 aut., 3 aut., 7 aut.); Department of Psychiatry, Sir Run Run Shaw Hospital, 3 East Qingchun Road/310016 Hangzhou, Zhejiang/Chine (4 aut.); Psychology Department at the St. George Campus, University of Toronto, 100 St. George Street, 4th Floor, Sidney Smith Hall/Toronto, Ontario, M5S 3G3/Canada (5 aut.); Cognitive, Perceptual and Brain Sciences, University College London, 26 Bedford Way/London WC1H 0AP/Royaume-Uni (1 aut., 6 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Neuropsychologia; ISSN 0028-3932; Coden NUPSA6; Royaume-Uni; Da. 2014; Vol. 53; Pp. 157-164; Bibl. 1/2 p.</SO>
<LA>Anglais</LA>
<EA>In the present study we address the following questions: (1) How is performance affected when patients with Parkinson's Disease (PD) perform a dynamic decision making task? (2) Does dopaminergic medication differentially affect dynamic decision making? To address these questions participants were trained with different goals during learning: either they made intervention-based decisions or prediction-based decisions during learning. The findings show that overall there is an advantage for those trained to intervene over those trained to predict. In addition, the results are the first demonstration that PD patients 'ON' (N=20) compared to 'OFF' L-Dopa (N=15) medication and also relative to healthy age matched controls (N=16) showed lower levels of relative improvement in the accuracy of their decisions in a dynamic decision making task, and tended to use sub-optimal strategies. These findings provide support for the 'Dopamine Overdose' hypothesis using a novel decision making task, and suggest that executive functions such as decision making can be adversely affected by dopaminergic medication in PD.</EA>
<CC>002B18C13; 002B17G; 002B17A01</CC>
<FD>Dopamine; Prise de décision; Maladie de Parkinson; Prédiction; Surdosage; Apprentissage; Antiparkinsonien; Homme</FD>
<FG>Catécholamine; Neurotransmetteur; Cognition; Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du   système nerveux central; Pathologie du   système nerveux; Processus acquisition</FG>
<ED>Dopamine; Decision making; Parkinson disease; Prediction; Overdosing; Learning; Antiparkinson agent; Human</ED>
<EG>Catecholamine; Neurotransmitter; Cognition; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Nervous system diseases; Acquisition process</EG>
<SD>Dopamina; Toma decision; Parkinson enfermedad; Predicción; Sobredosificación; Aprendizaje; Antiparkinsoniano; Hombre</SD>
<LO>INIST-11143.354000505714970160</LO>
<ID>14-0055586</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000040 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000040 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:14-0055586
   |texte=   The effects of dopaminergic medication on dynamic decision making in Parkinson's disease
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

The effects of dopaminergic medication on dynamic decision making in Parkinson's disease

The effects of dopaminergic medication on dynamic decision making in Parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri